Created at	Source	Raw Value	Validated value
May 12, 2022, 6 p.m.	eu	The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, at 6 months (+/- 4 weeks) after the 2nd dose of a mRNA anti-SARS-CoV-2 vaccine.	The proportion of subjects that have detectable titers of specific antibody against SARS-CoV-2 spike protein, measured by Elecsys® Anti-SARS-CoV-2 S, at 6 months (+/- 4 weeks) after the 2nd dose of a mRNA anti-SARS-CoV-2 vaccine.